Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Subscribe To Our Newsletter & Stay Updated
